India’s Pharma Industry Is Going Global. But Can It Catch up to China?

Why It Matters

The acquisition signals India’s intent to reshape the global pharma hierarchy, while the nation’s ability to innovate will determine whether it can capture market share from China and meet rising demand for advanced therapeutics.

Key Takeaways

• Sun Pharma aims for top‑25 spot with $12.5 bn revenue.
• India leads generic market, supplies 20% of unbranded drugs worldwide.
• Infrastructure and capital gaps hinder rapid shift to innovation.
• U.S. Biosecure Act could redirect supply chains toward India.
• No concrete government plan yet; competition rising from Southeast Asia.

Pulse Analysis

India’s pharmaceutical sector has long been the world’s “pharmacy of the world,” supplying a fifth of all unbranded medicines and boasting a $55 billion domestic market. Sun Pharma’s $11.75 billion acquisition of Organon marks a strategic pivot from pure generics to a broader portfolio that includes specialty and branded drugs. By consolidating revenues to roughly $12.5 billion and expanding its presence to 150 countries, the company aims to join the elite tier of global drugmakers, signaling confidence that Indian firms can compete on scale and brand recognition.

Despite the ambition, India faces structural hurdles that differentiate its trajectory from China’s. The country’s manufacturing base is extensive—over 10,000 facilities and 3,000 companies—but quality standards, data integrity, and R&D infrastructure lag behind. Capital scarcity limits large‑scale biotech investments, and the talent pipeline for cutting‑edge research has not yet returned in force, unlike the tech sector’s reverse brain‑drain. Regulatory consistency and government‑driven incentives remain vague, leaving firms to navigate an uncertain policy landscape while competitors such as Vietnam begin to carve out niche capabilities.

Geopolitical dynamics add a compelling layer to India’s growth prospects. The U.S. Biosecure Act, aimed at reducing reliance on Chinese supply chains, could open doors for Indian manufacturers willing to meet stringent quality and security criteria. With more than $19 billion earmarked for U.S. manufacturing, facilities, and R&D, Indian firms are positioning themselves as viable alternatives. However, the speed at which they can build the necessary infrastructure and secure regulatory approvals will dictate whether they merely fill a gap or evolve into a genuine innovation hub capable of challenging China’s emerging biotech dominance.